Abstract
The low-density lipoprotein receptor (LDLR) is a membrane receptor that mediates the endocytosis of low-density lipoprotein (LDL). Uptake of LDL has been proposed to contribute to chemotherapy resistance of acute myeloid leukaemia (AML) cell lines in vitro. In the present study, we analysed LDLR expression and survival using bone marrow biopsies from 187 intensively treated patients with AML. Here, increasing LDLR expression was associated with decreasing overall (58·4%, 44·2%, and 24·4%; P = 0·0018), as well as event-free survival (41·7%, 18·1%, and 14·3%; P = 0·0077), and an increasing cumulative incidence of relapse (33·9%, 55·1%, and 71·4%; P = 0·0011). Associations of LDLR expression with survival were confirmed in 557 intensively treated patients from two international validation cohorts. In the analytic and validation cohorts, LDLR expression remained associated with outcome in multivariable regression analyses including the European LeukemiaNet genetic risk classification. Thus, LDLR predicts outcome of patients with AML beyond existing risk factors. Furthermore, we found low expression levels of LDLR in most healthy tissues, suggesting it as a promising target for antibody-based pharmacodelivery approaches in AML.
References
Apr 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S VitolsK Söderberg-Reid
Jun 1, 1997·Lipids·R C MaranhãoF Pileggi
Jul 14, 1998·Nature Medicine·J KononenO P Kallioniemi
Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
May 27, 2004·Blood·Deborah E BankerRichard A Zager
Jun 15, 2005·Annual Review of Biochemistry·Hyesung Jeon, Stephen C Blacklow
Oct 8, 2008·Haematologica·Roel G W VerhaakPeter J M Valk
Nov 3, 2009·Blood·Hartmut DöhnerUNKNOWN European LeukemiaNet
Feb 9, 2010·Leukemia Research·Wah-Seng LimLawrence D Mayer
Nov 8, 2011·Cancer Discovery·Deliang GuoPaul S Mischel
Nov 6, 2012·Cancer Discovery·Anna SukhanovaIgor Astsaturov
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Apr 2, 2014·Blood·Jeffrey E LancetEric J Feldman
May 30, 2014·Nature·Min-Sik KimAkhilesh Pandey
Feb 13, 2015·Cancer Immunology Research·Christoph SchliemannWolfgang E Berdel
Feb 13, 2015·Proceedings of the National Academy of Sciences of the United States of America·Fabienne GuillaumondSophie Vasseur
Nov 27, 2015·FEBS Letters·Ryuji YamaguchiKiichi Hirota
Dec 4, 2015·Nature Protocols·Nicole BäumerSebastian Bäumer
Dec 23, 2015·Oncogenesis·D V WengeJ-H Mikesch
Jul 1, 2016·Prostate International·Yosuke FuruyaKazuhiro Suzuki
Nov 30, 2016·Blood·Hartmut DöhnerClara D Bloomfield
Mar 23, 2017·Molecular Therapy. Nucleic Acids·Oliver BrabetzJan-Henrik Mikesch
May 11, 2017·Lipids·Hasanuzzaman BhuiyanSigurd Vitols
Jul 1, 2017·Leukemia·L AngenendtC Schliemann
Aug 2, 2017·Oncogene·E J GallagherD LeRoith
Feb 3, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Margaretha G M RoemerMargaret A Shipp
May 11, 2018·Leukemia·Nasrin RastgooHong Chang
Jun 2, 2018·The European Respiratory Journal·Jan-Henrik MikeschMaria-Francisca Arteaga
Jun 7, 2018·Cellular Oncology (Dordrecht)·Jan-Henrik MikeschInga Grünewald
Jun 28, 2018·Cellular Oncology (Dordrecht)·Linus AngenendtInga Grünewald
Jul 20, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey E LancetBruno C Medeiros
Aug 5, 2018·Haematologica·Juliette LambertSylvie Castaigne
Jun 12, 2019·Leukemia·Linus AngenendtChristoph Schliemann